<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LITHANE- lithium carbonate tablet </strong><br>Miles Pharmaceuticals<br></p></div>
<h1>LITHANE®<br>(lithium carbonate)<br>TABLETS<br>For Control of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic Episodes</span> in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span>-Depressive Psychosis </h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Lithium carbonate is a white, light, alkaline powder with molecular formula Li<span class="Sub">2</span>CO<span class="Sub">3</span> and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.</p>
<p>Inert ingredients are: Blue 1 Lake; dibasic calcium phosphate; magnesium stearate; polyethylene glycol; sodium lauryl sulfate; starch; Yellow 5 Lake.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3"></a><p></p>
<h1>ACTIONS</h1>
<p class="First">Preclinical studies have shown that lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of lithium action in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Lithium carbonate is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-depressive patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
<p><span class="Bold">Typical symptoms</span> of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> include pressure of speech, motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, and possibly <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>. When given to a patient experiencing a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>, lithium may produce a normalization of symptomatology within 1 to 3 weeks.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>, and to patients receiving diuretics, since the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> is very high in such patients. If the psychiatric indication is life-threatening, and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.</p>
<p>Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, with <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>. Such patients should be carefully managed to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> with resulting lithium retention and toxicity. This condition is usually reversible when lithium is discontinued.</p>
<p>Morphologic changes with glomerular and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and nephron <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-depressive patients never exposed to lithium. The relationship between renal functional and morphologic changes and their association with lithium therapy have not been established.</p>
<p>When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> following a period of water deprivation, or 24 hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.</p>
<p>Lithium therapy has been reported in some cases to be associated with morphologic changes in the kidneys. The relationship between such changes and renal function has not been established.</p>
<p>An encephalopathic syndrome (characterized by <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, elevated serum enzymes, BUN and FBS) followed by irreversible <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> has occurred in a few patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. The possibility of similar adverse interactions with other antipsychotic medication exists.</p>
<p><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> is closely related to serum lithium levels, and can occur at doses close to therapeutic levels (see <a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Outpatients and their families should be warned that the patient must discontinue lithium carbonate therapy and contact his physician if such clinical signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, mild <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> occur.</p>
<p>Lithium carbonate may impair mental and/or physical abilities. Caution patients about activities requiring alertness (e.g., operating vehicles or machinery).</p>
<p>Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Adverse effects on nidation in rats, embryo viability in mice, and metabolism <span class="Italics">in vitro</span> of rat testis and human spermatozoa have been attributed to lithium, as have <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in sub-mammalian species and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in mice. Studies in rats, rabbits, and monkeys have shown no evidence of lithium-induced teratology.</p>
<p>In humans, lithium carbonate may cause fetal harm when administered to a pregnant woman. Data from lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein's anomaly. If this drug is used during pregnancy, or if a patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>There are lithium birth registries in the United States and elsewhere; however there is at the present time insufficient data to determine the effects of lithium carbonate on human fetuses. Therefore, at this point, lithium should not be used in pregnancy, especially the first trimester, unless in the opinion of the physician, the potential benefits outweigh the possible hazards.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Usage in Nursing Mothers</h2>
<p class="First">Lithium is excreted in human milk. Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">Since information regarding the safety and effectiveness of lithium carbonate in children under 12 years of age is not available, its use in such patients is not recommended at this time. There has been a report of a transient syndrome of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> and <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> occurring in a 15 kg child who ingested 300 mg of lithium carbonate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The ability to tolerate lithium is greater during the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase and decreases when <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms subside (see <a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a>).</p>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Caution should be used when lithium and diuretics or angiotensin converting enzyme (ACE) inhibitors are used concomitantly because sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. When such combinations are used, the lithium dosage may need to be decreased, and more frequent monitoring of lithium plasma levels is recommended.</p>
<p>The distribution space of lithium approximates that of total body water. Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of lithium is proportional to its plasma concentration. The half-life of elimination of lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">sodium depletion</span>. Therefore, it is essential for the patient to maintain a normal diet, including salt, and an adequate fluid intake (2500–3000 ml) at least during the initial stabilization period. Decreased tolerance to lithium has been reported to ensue from protracted <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and, if such occur, supplemental fluid and salt should be administered.</p>
<p><span class="Bold">In addition to <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>,</span> concomitant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with elevated temperatures may also necessitate a temporary reduction or cessation of medication.</p>
<p>Previously existing underlying <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">thyroid disorders</span> do not necessarily constitute a contraindication to lithium treatment; where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any; where <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used.</p>
<p>This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible individuals. Although the over-all incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>Indomethacin and piroxicam have been reported to increase significantly, steady state plasma lithium levels. In some cases <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> has resulted from such interactions. There is also some evidence that other nonsteroidal, anti-inflammatory agents may have a similar effect. When such combinations are used, increased plasma lithium level monitoring is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions are seldom encountered at serum lithium levels below 1.5 mEq./l., except in the occasional patient sensitive to lithium. Mild to moderate toxic reactions may occur at levels from 1.5–2.5 mEq./l., and moderate to severe reactions may be seen at levels from 2.0–2.5 mEq./l., depending upon individual response to the drug.</p>
<p>Fine hand <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, and mild <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> may occur during initial therapy for the acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> phase, and may persist throughout treatment. Transient and mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">general discomfort</span> may also appear during the first few days of lithium administration.</p>
<p>These side effects are an inconvenience rather than a disabling condition, and usually subside with continued treatment or a temporary reduction or cessation of dosage. If persistent, a cessation of dosage is indicated.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">lack of coordination</span> may be early signs of lithium <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, and can occur at lithium levels below 2.0 mEq./l. At higher levels, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and a large output of dilute urine may be seen. Serum lithium levels above 3.0 mEq./l. may produce a complex clinical picture involving multiple organs and organ systems. Serum lithium levels should not be permitted to exceed 2.0 mEq./l. during the acute treatment phase.</p>
<p>The following reactions have been reported and appear to be related to serum lithium levels, including levels within the therapeutic range:</p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Neurological:</span> Cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>) have been reported with lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> due to <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>. Lithium should be discontinued, if clinically possible, if this syndrome occurs.</dd>
<dt> </dt>
<dd>
<span class="Bold">Neuromuscular:</span> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, muscle hyperirritability (<span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> of whole limbs), <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, choreo-athetotic movements, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> deep tendon reflexes.</dd>
<dt> </dt>
<dd>
<span class="Bold">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">blackout spells</span>, epileptiform <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">incontinence of urine</span> or feces, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span>, and downbeat <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Dermatologic:</span> drying and thinning of hair, anesthesia of skin, chronic <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, xerosis cutis, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</dd>
<dt> </dt>
<dd>
<span class="Bold">Thyroid Abnormalities:</span> <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Euthyroid goiter</span> and/or <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> (including <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>) accompanied by lower T<span class="Sub">3</span> and T<span class="Sub">4</span>. I<span class="Sup">131</span> iodine uptake may be elevated. (See <a href="#PRECAUTIONS">Precautions</a>.) Paradoxically, rare cases of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> have been reported.</dd>
<dt> </dt>
<dd>
<span class="Bold">EEG. Changes:</span> diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm.</dd>
<dt> </dt>
<dd>
<span class="Bold">EKG. Changes:</span> reversible flattening, isoelectricity or inversion of T-waves.</dd>
<dt> </dt>
<dd>
<span class="Bold">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, tendency to sleep, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, transient scotomata.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Miscellaneous reactions unrelated to dosage are:</span> transient electroencephalographic and electrocardiographic changes, leucocytosis, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, diffuse non-toxic <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with or without <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span> with or without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, cutaneous <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, worsening of <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">organic brain syndromes</span>, excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, edematous <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of ankles or wrists, and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, sometimes resembling <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>, and metallic taste. A single report has been received of the development of painful discoloration of fingers and toes and <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> of the extremities within one day of the starting of treatment of lithium. The mechanism through which these symptoms (resembling Raynaud's Syndrome) developed is not known. Recovery followed discontinuance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Acute Mania</span></h2>
<p class="First">Optimal patient response to lithium carbonate usually can be established and maintained with 600 mg t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq./l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient's clinical state and of serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Long term Control</h2>
<p class="First">The desirable lithium levels are 0.6 to 1.2 mEq./l. Dosage will vary from one individual to another, but usually 300 mg t.i.d. or q.i.d will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.</p>
<p>Patients abnormally sensitive to lithium may exhibit toxic signs at serum levels of 1.0 to 1.5 mEq./l. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>N.B.</h2>
<p class="First">Blood samples for serum lithium determinations should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8–12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxic levels for lithium are close to the therapeutic levels. It is therefore important that patients and their families be cautioned to watch for early toxic symptoms and to discontinue the drug and inform the physician should they occur. Toxic symptoms are listed in detail under <a href="#ADVERSE">ADVERSE REACTIONS</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">No specific antidote for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span> is known. Early symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> can usually be treated by reduction or cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium poisoning</span>, the first and foremost goal of treatment consists of elimination of this ion from the organism.</p>
<p>Treatment is essentially the same as that used in barbiturate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>: 1) lavage, 2) correction of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, and 3) regulation of kidney functioning. Urea, mannitol, and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Lithane (lithium carbonate) is available as scored tablets containing 300 mg of lithium carbonate in bottles of 100 (NDC 0026-2951-51), and 1000 (NDC 0026-2951-54).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Manufactured for<br><span class="Bold">Miles Pharmaceuticals</span><br>Division of Miles Laboratories, Inc.<br>West Haven, Connecticut 06516 USA<br>by Pfizer Inc., New York, N.Y. 10017</p>
<p>LAB-0140-2.0</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LITHANE 		
					</strong><br><span class="contentTableReg">lithium carbonate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-2951</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lithium carbonate</strong> (lithium) </td>
<td class="formItem"></td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Blue 1 Lake</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>dibasic calcium phosphate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Yellow 5 Lake</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (GREEN) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (convex) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Miles;951</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-2951-51</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0026-2951-54</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Miles Pharmaceuticals</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>42BED965-4B8F-4471-BCC9-091F87238653</div>
<div>Set id: 42BED965-4B8F-4471-BCC9-091F87238653</div>
<div>Version: 1</div>
<div>Effective Time: 20060612</div>
</div>
</div> <div class="DistributorName">Miles Pharmaceuticals</div></p>
</body></html>
